

## Grifols publishes its 2020 Integrated Annual Report as part of its commitment to sustainability

- *The report provides stakeholders with a comprehensive view of Grifols' commitment to long-term growth and innovation, robust corporate governance and environment and social responsibility factors, aligned with its efforts to contribute to the Sustainable Development Goals (SDGs)*
- *The report fully complies with the requirements and recommendations of the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) and has been approved by Grifols' Board of Directors and verified by an independent external auditor*

**Barcelona, March 4, 2021.-** Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare leader in the production of plasma-derived medicines with a proven track record of more than 100 years dedicated to enhancing the health and well-being of people worldwide, released the publication of its 2020 Integrated Annual Report, in addition to other corporate sustainability reports: Sustainable Development Goals (SDGs) set by the United Nations, Grifols' Socio-Economic Impact, Management of Risks and Opportunities Related to Climate Change, and two new publications, one outlining Grifols' Social Impact and another regarding its Commitment to Our Donors.

The Integrated Annual Report offers an in-depth analysis of Grifols' solid financial results; its commitment to long-term growth and innovation; robust corporate governance; and dedication to promoting environmental and social factors.

In terms of GDP contribution and job creation, Grifols' activity in 2020 generated an economic impact of EUR 7,500 million and contributed to 140,000 new jobs (direct, indirect and induced) in the United States, Spain, Germany and Ireland.

Using the social return on investment (SROI) methodology, Grifols also completed its first study to measure the social value generated by its 252 U.S.-based plasma centers. Based on this analysis, Grifols' operations created a EUR 6,200 million impact on donors, patients and local communities, of which approximately 59% corresponds to patients, 30% to donors and the remaining 11% to local communities.

# GRIFOLS

## Sustainability at Grifols in 2020

7,500M€

**TOTAL  
ECONOMIC IMPACT**

140,000

**JOBS  
CREATED**

6,200M€

**SOCIAL  
VALUE**

In terms of its human resources, Grifols continued to reinforce its commitment to diversity, employee development, talent promotion, equal opportunities and gender equality. Women make up 60% of the workforce at Grifols, whose adjusted salary gap is below the market average in its countries of operation.

23,655

**WORKFORCE  
60% WOMEN**

41M€

**SOCIAL  
INVESTMENTS**

23M€

**ENVIRONMENT  
INITIATIVES**

Approved by Grifols' Board of Directors and verified by an independent external auditor, the 2020 Integrated Annual Report fully complies with the requirements and recommendations of the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB).

Grifols is recognized among the world's most sustainable companies and listed on the Dow Jones Sustainability Index, Euronext Vigeo, FTSE4Good and Bloomberg Gender Equality Index.

More details are available [here](#) in Grifols' 2020 Integrated Annual Report and in the related sustainability reports.

## Investor contact:

### Investor Relations

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Phone number: +34 93 571 02 21

## Media contacts:

Raquel Lumbreras [raquel\\_lumbreras@duomocomunicacion.com](mailto:raquel_lumbreras@duomocomunicacion.com)

Borja Gómez [borja\\_gomez@duomocomunicacion.com](mailto:borja_gomez@duomocomunicacion.com)

Duomo Comunicación Grifols PR office

Phone number: +34 91 311 92 89 - 91 311 92 90

---

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [Grifols.com](http://Grifols.com)

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.